Bernhard K Keppler Selected Research

Hypoxia (Hypoxemia)

1/2023	A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
3/2021	Development of a cobalt(iii)-based ponatinib prodrug system.
12/2020	Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.
1/2020	Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
11/2018	Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis.
11/2016	Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs.
4/2016	Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bernhard K Keppler Research Topics

Disease

159	Neoplasms (Cancer) 03/2024 - 01/2002
29	Carcinoma (Carcinomatosis) 03/2021 - 01/2005
14	Colonic Neoplasms (Colon Cancer) 07/2023 - 01/2004
8	Colorectal Neoplasms (Colorectal Cancer) 04/2022 - 01/2004
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2020 - 08/2008
7	Hypoxia (Hypoxemia) 01/2023 - 04/2016
4	Teratocarcinoma 03/2023 - 12/2015
4	Ovarian Neoplasms (Ovarian Cancer) 08/2019 - 01/2004
3	Leukemia 12/2022 - 03/2021
3	Neoplasm Metastasis (Metastasis) 12/2021 - 08/2015
3	Hematologic Diseases (Blood Diseases) 01/2020 - 01/2016
3	Osteosarcoma (Osteogenic Sarcoma) 11/2018 - 10/2008
3	Adenocarcinoma 01/2012 - 11/2007
2	Inflammation (Inflammations) 09/2023 - 01/2008
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2022 - 01/2004
2	Lymphoma (Lymphomas) 12/2022 - 01/2004
2	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2016
2	Melanoma (Melanoma, Malignant) 01/2020 - 10/2009
2	Lung Neoplasms (Lung Cancer) 06/2017 - 10/2014
2	Leukemia L1210 01/2017 - 01/2014
2	Necrosis 03/2015 - 10/2014
2	Hepatocellular Carcinoma (Hepatoma) 10/2013 - 10/2008
1	Bile Duct Neoplasms (Bile Duct Cancer) 11/2023
1	Acidosis 01/2023
1	Hyperthermia 10/2022

Drug/Important Bio-Agent (IBA)

38	PlatinumIBA 01/2024 - 06/2003
32	Cisplatin (Platino)FDA LinkGeneric 09/2023 - 01/2005
30	LigandsIBA 03/2024 - 06/2003
29	RutheniumIBA 11/2023 - 06/2005
23	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2023 - 01/2004
20	MetalsIBA 01/2022 - 01/2004
19	ProdrugsIBA 01/2024 - 07/2015
13	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 09/2022 - 01/2010
12	GalliumIBA 12/2022 - 01/2002
10	OsmiumIBA 01/2022 - 08/2008
9	KP 1339IBA 11/2023 - 06/2010
9	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 12/2006
9	ThiosemicarbazonesIBA 11/2021 - 06/2012
8	IndazolesIBA 01/2019 - 06/2005
8	indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA 07/2014 - 08/2005
7	IronIBA 01/2024 - 01/2004
7	Coordination ComplexesIBA 08/2019 - 06/2003
6	Tyrosine Kinase InhibitorsIBA 03/2021 - 11/2016
6	Proteins (Proteins, Gene)FDA Link 12/2019 - 05/2008
6	4-cymene (p-cymene)IBA 10/2018 - 05/2009
5	Antineoplastic Agents (Antineoplastics)IBA 12/2021 - 11/2006
4	AlbuminsIBA 01/2024 - 03/2017
4	RhodiumIBA 01/2023 - 08/2018
4	SolutionsIBA 01/2023 - 01/2014
4	SodiumIBA 01/2019 - 06/2015
4	diphenyl (biphenyl)IBA 03/2013 - 10/2008
3	maleimideIBA 01/2024 - 03/2017
3	ElementsIBA 08/2022 - 01/2021
3	CopperIBA 11/2020 - 09/2012
3	Peptides (Polypeptides)IBA 06/2017 - 07/2013
3	CationsIBA 11/2009 - 01/2004
3	Ruthenium CompoundsIBA 08/2008 - 06/2007
2	Platinum Compounds (Compounds, Platinum)IBA 02/2023 - 04/2016
2	IridiumIBA 01/2022 - 01/2020
2	Estrone FDA Link 10/2021 - 01/2021
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2021 - 01/2019
2	ponatinibIBA 03/2021 - 11/2018
2	CobaltIBA 03/2021 - 12/2020
2	Oxygen (Dioxygen)IBA 03/2021 - 11/2016
2	IsotopesIBA 01/2021 - 06/2014
2	Glutathione (Reduced Glutathione)IBA 11/2020 - 02/2013
2	Biotin (Vitamin H)FDA Link 01/2019 - 03/2015
2	Carboplatin (JM8)FDA LinkGeneric 11/2018 - 03/2015
2	Arsenic Trioxide (Trisenox)FDA Link 02/2017 - 01/2004
2	IntegrinsIBA 01/2017 - 10/2014
2	NKP-1339IBA 01/2017 - 01/2016
2	Blood Proteins (Serum Proteins)IBA 01/2016 - 12/2009
2	VanadiumIBA 11/2015 - 06/2015
2	CymenesIBA 03/2013 - 11/2009
2	Transferrin (beta 2 Transferrin)IBA 02/2013 - 11/2006
2	CarbohydratesIBA 01/2013 - 01/2008
2	Human Serum Albumin FDA LinkGeneric 12/2011 - 07/2007
2	BenzazepinesIBA 12/2011 - 08/2010
2	BromidesIBA 10/2009 - 12/2008
2	tris(8-quinolinolato)gallium (III)IBA 11/2006 - 01/2004
2	gallium nitrate FDA Link 01/2004 - 01/2004
2	Transferrin Receptors (Transferrin Receptor)IBA 01/2004 - 01/2004
2	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2004 - 01/2004
1	VLX600IBA 01/2024
1	Gemcitabine FDA Link 01/2024
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 09/2023
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 07/2023
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 07/2023
1	PAMAM StarburstIBA 05/2023
1	Dendrimers (Dendrons)IBA 05/2023
1	1-methylimidazoleIBA 01/2023
1	Vincristine (Oncovin)FDA LinkGeneric 12/2022
1	Daunorubicin (Cerubidine)FDA LinkGeneric 12/2022
1	Protective AgentsIBA 12/2022
1	carbeneIBA 06/2022

Therapy/Procedure

24	Therapeutics 11/2023 - 01/2004
11	Drug Therapy (Chemotherapy) 10/2022 - 01/2004
3	Laser Therapy (Surgery, Laser) 11/2020 - 08/2015
2	Transplantation 11/2018 - 08/2012
2	Aftercare (After-Treatment) 01/2017 - 04/2015